Commentary on how medicinal cannabis can evolve in a similar manner as the pharmaceutical industry did.
A long history of cannabis discoveries and research has put Israel at the forefront of medical cannabis developments, worldwide collaborations, and investor activity.
From 9/11 First Responder to Cancer Survivor and Cannabis Entrepreneur: How One Man’s Cannabis Journey Is Impacting the Medicinal Field
Aryn Sieber, the founder and CEO of CBD Essentials and Cannaisseur Brands as well as the founder of CannaCauses Foundation, discusses his experiences as a 9/11 first responder, his battle with stage IV cancer, and how cannabis impacted his life.
A review of the literature to examine the analgesic properties of cannabis.
What changes need to be adopted in our industry to make the transition to the pharmaceutical industry testing paradigm?
GW Pharmaceuticals recently announced the company’s financial results from the second quarter of 2019.
Big Pharma is working on locking up cannabis patents, creating partnerships, and standing by to use its financial muscle for more ownership of the medical cannabis industry when the time is right.
Beyond Delta-9-THC and CBD: Current Evidence for Medical Benefit of Terpenes and Less Studied Cannabinoids
Lesser known cannabinoids and terpenes may be helpful for patients. Here the author shows why, and how patients can choose more effective medical cannabis products.
By understanding whole-plant extractions better, businesses will be able to better plan for long-term profitability and sustainability.
David L. Nathan, MD, DFAPA, President, Board of Directors, Doctors for Cannabis Regulations (DFCR), discusses how the DFCR was formed, the efforts they have been making in the cannabis field, and plans for the future of the organization.